Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...

Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88. The company has a market capitalization of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, and Crescent Biopharma. They have collectively raised approximately $2.7 billion and currently have four programs in clinical development.

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...